Poisons List Amendment Order (No. 2) 1999
I make the following order under the Poisons Act 1971 .
9 June 1999JUDY JACKSON
Minister for Health and Human Services
This order may be cited as the Poisons List Amendment Order (No. 2) 1999 .
This order takes effect on the day on which its making is notified in the Gazette.
In this order, the Poisons List Order 1998 is referred to as the Principal Order.
4. Schedule 2 amended (Medicinal Poisons)
Schedule 2 to the Principal Order is amended as follows:(a) by inserting after paragraph (c) in item 2064 the following:
2064M.
Isoconazole for human use in dermal preparations.
(b) by inserting after item 2069 the following:
2069M.
Lithium for dermal use in preparations containing 1% or less of lithium except in preparations containing 0.01% or less of lithium.
(c) by omitting item 2083 and substituting the following:
2083.
Naproxen in divided preparations containing 250mg or less of naproxen per dosage unit in packs of 20 or less dosage units for the treatment of dysmenorrhoea.
(d) by omitting item 2089 and substituting the following:
2089.
Oxethazaine (oxetecaine) in preparations for internal use.
(e) by omitting item 2118 and substituting the following:
2118.
Terbinafine in preparations for dermal use.
(f) by inserting after subparagraph (iv) in paragraph (b) of item 2120 the following:
2120E.
Tioconazole in preparations for dermal use.
5. Schedule 3 amended (Potent Substances)
Schedule 3 to the Principal Order is amended as follows:(a) by omitting item 3005 and substituting the following:
3005.
Azatadine in oral preparations.
3005M.
Beclomethasone in aqueous nasal sprays delivering 50 micrograms or less per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the treatment of seasonal and allergic rhinitis.
(b) by omitting items 3007 and 3008 and substituting the following:
3007.
Brompheniramine in oral preparations except when included in Schedule 2 .
3008.
Buclizine in oral preparations.
3008E.
Budesonide in aqueous nasal sprays delivering 50 micrograms or less per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the treatment of seasonal and allergic rhinitis.
(c) by omitting item 3011 and substituting the following:
3011.
Chlorpheniramine in oral preparations except when included in Schedule 2 .
(d) by omitting item 3013 and substituting the following:
3013.
Clemastine in oral preparations.
(e) by omitting items 3015 , 3016 and 3017 and substituting the following:
3015.
Codeine when –
(a) compounded with aspirin, paracetamol, salicylamide, or any of their derivatives, and no other analgesic substance, in divided preparations containing not more than 10mg of codeine per dosage unit; and
(b) labelled with a recommended dose not exceeding 15mg of codeine –
except when included in Schedule 2 .
3016.
Cyproheptadine in oral preparations.
3017.
Dexchlorpheniramine in oral preparations except when included in Schedule 2 .
(f) by omitting item 3019 and substituting the following:
3019.
Dimenhydrinate in oral preparations except when included in Schedule 2 .
(g) by omitting item 3021 and substituting the following:
3021.
Diphenhydramine in oral preparations except when included in Schedule 2 .
(h) by omitting items 3022 and 3023 and substituting the following:
3022.
Diphenylpyraline in oral preparations except when included in Schedule 2 .
3023.
Dithranol for therapeutic use.
3023M.
Doxylamine in oral preparations except when included in Schedule 2 .
(i) by inserting after item 3027 the following:
3027M.
Flunisolide in aqueous nasal sprays delivering 25 micrograms or less per actuation when the maximum recommended daily dose is no greater than 200 micrograms, for the treatment of seasonal and allergic rhinitis.
(j) by inserting after paragraph (b) in item 3032 the following:
3032M.
Ibuprofen in undivided preparations for oral use labelled with a recommended daily dose of not more than 1 200mg of ibuprofen.
(k) by omitting item 3035 and substituting the following:
3035.
Isoconazole in preparations for vaginal use.
(l) by omitting items 3037 , 3038 and 3039 and substituting the following:
3037.
Mepyramine in oral preparations.
3038.
Methdilazine in oral preparations.
3039.
Miconazole for human use in topical preparations –
(a) for the treatment of oral candidiasis; or
(b) for vaginal use.
(m) by inserting after item 3039E the following:
3039S.
Naproxen in divided preparations containing 250mg or less of naproxen per dosage unit in packs of 30 or less dosage units except when included in Schedule 2 .
(n) by omitting item 3040 and substituting the following:
3040.
Nicotine as an aid in withdrawal from tobacco smoking –
(a) in chewing gum containing 4mg or less of nicotine except when included in Schedule 2 ; or
(b) in patches for transdermal delivery; or
(c) in cartridges for oral inhalation containing 10mg or less of nicotine per dosage unit.
(o) by omitting item 3043 and substituting the following:
3043.
Pheniramine in oral preparations except when included in Schedule 2 .
(p) by omitting item 3045 and substituting the following:
3045.
Phenyltoloxamine in oral preparations.
(q) by omitting item 3048 and substituting the following:
3048.
Promethazine in oral preparations except when included in Schedule 2 .
(r) by inserting after item 3052 the following:
3052E.
Selenium in preparations for oral human use with a recommended daily dose of 100 micrograms or less of selenium except in preparations for oral human use with a recommended daily dose of 26 micrograms or less of selenium.
(s) by omitting item 3055 and substituting the following:
3055.
Thenyldiamine in oral preparations except when included in Schedule 2 .
(t) by omitting items 3057 , 3058 , 3059 and 3060 and substituting the following:
3057.
Tioconazole in preparations for vaginal use.
3058.
Triamcinolone acetonide for the treatment of mouth ulcers, in preparations containing 0.1% or less of triamcinolone in a pack of 5g or less.
3059.
Trimeprazine in oral preparations other than –
(a) preparations included in Schedule 2 ; or
(b) liquid preparations containing more than 10mg/5ml of trimeprazine.
3060.
Triprolidine in oral preparations except when included in Schedule 2 .
6. Schedule 4 amended (Restricted Substances)
Schedule 4 to the Principal Order is amended as follows:(a) by inserting before item 40001 the following:
40000M.
Abciximab.
(b) by inserting after item 40005 the following:
40005M.
Acetarsol.
(c) by inserting after item 40007 the following:
40007E.
Acetylcarbromal.
(d) by inserting after item 40009 the following:
40009E.
Acetyldigitoxin.
(e) by inserting after item 40010 the following:
40010E.
Acetylstrophanthidin.
40009S.
Acipimox.
(f) by inserting after paragraph (b) in item 40022 the following:
40022E.
Alclofenac.
(g) by inserting after item 40026 the following:
40026E.
Alendronic acid.
40026M.
Alfacalcidol.
(h) by inserting after item 40028 the following:
40028M.
Allergens.
(i) by inserting after item 40035 the following:
40035M.
Alseroxylon.
(j) by omitting item 40051 and substituting the following:
40051.
Aminophenazone (amidopyrine) and derivatives for the treatment of animals.
(k) by inserting after item 40062 the following:
40062M
Ammonium bromide.
(l) by inserting after item 40064 the following:
40064E.
Amoxapine.
(m) by inserting after item 40068 the following:
40068E.
Amrinone.
(n) by omitting item 40073 and substituting the following:
40073.
Anabolic and androgenic steroidal agents except when separately specified in these Schedules.
(o) by inserting after item 40074 the following:
40074S.
Ancrod and its immunoglobulin antidote.
(p) by omitting item 40080 and substituting the following:
40080.
Antigens for human therapeutic use except when separately specified in these Schedules.
(q) by omitting items 40082 and 40083 and substituting the following:
40082.
Antimony organic compounds for therapeutic use except when separately specified in these Schedules.
40083.
Antisera (immunosera) for human parenteral use except when separately specified in these Schedules.
(r) by inserting after item 40086 the following:
40086M.
Apronal.
(s) by inserting after item 40087 the following:
40087E.
Arecoline.
(t) by omitting item 40088 and substituting the following:
40088.
Arsenic for human therapeutic use except when separately specified in these Schedules.
(u) by inserting after item 40098 the following:
40098M.
Aurothiomalate sodium.
(v) by inserting after paragraph (b) in item 40100 the following:
40100S.
Azacyclonol.
(w) by inserting after item 40102 the following:
40102E.
Azapropazone.
40102M.
Azarabine.
(x) by inserting after paragraph (b) in item 40112 the following:
40112E.
Bamethan.
(y) by omitting item 40116 and substituting the following:
40116.
Beclomethasone except when included in Schedule 3 .
(z) by omitting item 40119 and substituting the following:
40119.
Benactyzine.
(za) by inserting after item 40120 the following:
40120S.
Benethamine penicillin.
(zb) by inserting after item 40122 the following:
40122M.
Benoxaprofen.
40122S.
Benperidol.
(zc) by inserting after item 40124 the following:
40124M.
Benzathine penicillin.
(zd) by inserting after item 40130 the following:
40130M.
Benzthiazide.
(ze) by omitting item 40131 and substituting the following:
40131.
Benztropine (benzatropine).
(zf) by inserting after item 40133 the following:
40133E.
Bepridil.
40133M.
Beractant.
(zg) by inserting after item 40139 the following:
40139S.
Bezafibrate.
(zh) by inserting after paragraph (c) in item 40143 the following:
40143E.
Bisoprolol.
(zi) by omitting item 40152 and substituting the following:
40152.
Botulinum toxins for human use except when separately specified in these Schedules.
(zj) by omitting item 40156 and substituting the following:
40156.
Bromides, inorganic, for therapeutic use except when separately specified in these Schedules.
(zk) by omitting item 40163 and substituting the following:
40163.
Budesonide except when included in Schedule 3 .
(zl) by inserting after item 40165 the following:
40165M.
Buphenine.
(zm) by inserting after item 40166 the following:
40166E.
Buserelin.
(zn) by inserting after item 40177 the following:
40177M.
Calcium polystyrene sulphonate.
(zo) by inserting after item 40199 the following:
40199E.
Carboprost.
(zp) by inserting after item 40200 the following:
40200M.
Carbutamide.
(zq) by inserting after item 40201 the following:
40201S
Carisoprodol.
(zr) by inserting after item 40208 the following:
40208E.
Cefetamet.
40208M.
Cefixime.
(zs) by inserting after item 40209 the following:
40209M.
Cefonicid.
(zt) by inserting after item 40212 the following:
40212M.
Cefotiam.
(zu) by inserting after item 40215 the following:
40215S.
Cefsulodin.
(zv) by inserting after item 40216 the following:
40216E.
Ceftibuten.
(zw) by inserting after item 40219 the following:
40219E.
Celiprolol.
(zx) by omitting item 40226 and substituting the following:
40226.
Cephamandole (cefamandole).
(zy) by omitting item 40228 and substituting the following:
40228.
Cephazolin (cefazolin).
(zz) by inserting after item 40230 the following:
40230S.
Ceruletide.
(zza) by inserting after item 40250 the following:
40250M.
Chlorotrianisene.
(zzb) by omitting item 40287 and substituting the following:
40287.
Clobetasone (clobetasone-17-butyrate).
(zzc) by inserting after item 40288 the following:
40288E.
Clodronic acid (including sodium clodronate).
(zzd) by inserting after item 40297 the following:
40297M.
Clopidogrel.
(zze) by inserting after paragraph (b) in item 40306 the following:
40306S.
Co-dergocrine.
(zzf) by inserting after item 40318 the following:
40318M.
Co-trimoxazole.
(zzg) by inserting after item 40323 the following:
40323E.
Cyclobenzaprine.
(zzh) by inserting after item 40324 the following:
40324M.
Cycloheximide.
(zzi) by omitting items 40339 and 40340 and substituting the following:
40339.
Dalteparin (includes dalteparin sodium).
40340.
Danaparoid (includes danaparoid sodium).
(zzj) by inserting after item 40347 the following:
40347E.
Decamethonium.
40347M.
Deflazacort.
(zzk) by inserting after paragraph (b) in item 40394 the following:
40394E.
Dihydrogotoxine.
(zzl) by inserting after item 40400 the following:
40400E.
Dimercaprol.
(zzm) by omitting items 40409 and 40410 and substituting the following:
40409.
Dinitrocresols for therapeutic use except when separately specified in these Schedules.
40410.
Dinitronaphthols for therapeutic use except when separately specified in these Schedules.
(zzn) by inserting after item 40420 the following:
40420S.
Diphtheria toxoid.
(zzo) by omitting item 40423 ;(zzp) by inserting after item 40427 the following:
40427M.
Disulphamide.
(zzq) by omitting item 40429 and substituting the following:
40429.
Ditiocarb.
(zzr) by inserting after item 40435 the following:
40435M.
Dopexamine.
40435S.
Dornase.
(zzs) by inserting after item 40437 the following:
40437S.
Doxantrazole.
(zzt) by inserting after item 40450 the following:
40450E.
Ectylurea.
(zzu) by omitting item 40451 and substituting the following:
40451.
Edetic acid for human therapeutic use except –
(a) in preparations containing 0.25% or less of edetic acid; or
(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or
(c) in contact lens preparations.
40451M.
Edoxudine.
40451S.
Edrophonium.
(zzv) by inserting after item 40452 the following:
40452S.
Emepronium.
(zzw) by inserting after item 40458 the following:
40458E.
Enoximone.
40458M.
Enprostil.
(zzx) by inserting after item 40465 the following:
40465E.
Ergotamine.
40465M.
Ergotoxine.
(zzy) by inserting after item 40478 the following:
40478M.
Ethisterone.
(zzz) by omitting item 40491 and substituting the following:
40491.
Etidronic acid (includes disodium etidronate) except in toothpastes and gels containing 1% or less of etidronate.
(zzza) by inserting after item 40500 the following:
40500S.
Fenbufen.
(zzzb) by inserting after item 40509 the following:
40509S.
Fibrinolysin except for external use.
(zzzc) by inserting after item 40513 the following:
40513M.
Floctafenine.
40513S.
Fluanisone.
(zzzd) by omitting item 40522 and substituting the following:
40522.
Flunisolide except when included in Schedule 3 .
(zzze) by omitting item 40524 and substituting the following:
40524.
Fluocinolone acetonide.
40524E.
Fluocinonide.
(zzzf) by inserting after item 40534 the following:
40534S.
Flurandrenolone.
(zzzg) by inserting after item 40546 the following:
40546M.
Formestane.
(zzzh) by omitting item 40557 and substituting the following:
40557.
Galanthamine (galantamine).
(zzzi) by inserting after item 40567 the following:
40567M.
Gitalin.
(zzzj) by inserting after item 40572 the following:
40572M.
Glisoxepide.
(zzzk) by inserting after item 40573 the following:
40573S.
Glutathione for parenteral use.
(zzzl) by omitting item 40579 and substituting the following:
40579.
Gonadotrophic hormones except when separately specified in these Schedules.
(zzzm) by inserting after item 40588 the following:
40588E.
Hachimycin.
40588M.
Haematin.
40588S.
Haemophilus influenzae vaccine.
(zzzn) by inserting after item 40590 the following:
40590E.
Halofenate.
(zzzo) by inserting after item 40594 the following:
40594E.
Hepatitis A vaccine.
40594M.
Hepatitis B vaccine.
(zzzp) by inserting after item 40597 the following:
40597E.
Hexetidine for human internal use.
40597M.
Hexobendine.
(zzzq) by inserting after item 40598 the following:
40598M.
Histamine for therapeutic use except in preparations containing 0.5% or less of histamine.
(zzzr) by inserting after item 40601 the following:
40601E.
Hydrargaphen for internal use.
(zzzs) by omitting item 40620 and substituting the following:
40620.
Ibuprofen except when included in Schedule 2 or 3 .
40620M.
Ibuterol.
(zzzt) by inserting after item 40623 the following:
40623M.
Iloprost.
(zzzu) by omitting item 40626 and substituting the following:
40626.
Immunoglobulins for human parenteral use except when separately specified in these Schedules.
(zzzv) by inserting after item 40629 the following:
40629E.
Indoprofen.
40629M.
Indoramin.
40629S.
Influenza and coryza vaccines –
(a) for parenteral use; or
(b) for nasal administration.
(zzzw) by inserting after item 40631 the following:
40631M.
Iodothiouracil.
(zzzx) by inserting after item 40633 the following:
40633M.
Iprindole.
(zzzy) by omitting item 40642 and substituting the following:
40642.
Isoconazole except when included in Schedule 2 , 3 or 6 .
(zzzz) by inserting after item 40647 the following:
40647E.
Isoprinosine.
(zzzza) by inserting after item 40651 the following:
40651S.
Isoxicam.
(zzzzb) by inserting after paragraph (b) in item 40658 the following:
40658M.
Ketazolam.
(zzzzc) by inserting after item 40661 the following:
40661M.
Ketotifen.
(zzzzd) by inserting after item 40664 the following:
40664E.
Lacidipine.
(zzzze) by inserting after item 40668 the following:
40668M.
L-asparaginase.
(zzzzf) by omitting item 40673 and substituting the following:
40673.
Lead compounds for human therapeutic use except when separately specified in these Schedules.
(zzzzg) by inserting after item 40689 the following:
40689M.
Liquorice deglycyrrhizinised.
(zzzzh) by inserting after item 40690 the following:
40690M.
Lisuride.
(zzzzi) by omitting item 40691 and substituting the following:
40691.
Lithium for therapeutic use except –
(a) when included in Schedule 2 ; or
(b) in preparations containing 0.01% or less of lithium.
(zzzzj) by inserting after item 40694 the following:
40694M.
Lofexidine.
40694S.
Lomefloxacin.
(zzzzk) by inserting after item 40696 the following:
40696M.
Loprazolam.
(zzzzl) by inserting after item 40699 the following:
40699M.
Lormetazepam.
(zzzzm) by inserting after item 40706 the following:
40706M.
Mannomustine.
(zzzzn) by inserting after item 40708 the following:
40708M.
Measles vaccine.
40708S.
Mebanazine.
(zzzzo) by inserting after item 40711 the following:
40711M.
Mebutamate.
(zzzzp) by inserting after item 40712 the following:
40712E.
Mecasermin.
40712M.
Mecillinam.
40712S.
Meclocycline.
40712V.
Meclofenamate.
(zzzzq) by omitting item 40717 and substituting the following:
40717E.
Medigoxin (methyldigoxin).
(zzzzr) by inserting after item 40727 the following:
40727M.
Meningococcal vaccine.
40727S.
Menotrophin.
(zzzzs) by inserting after item 40731 the following:
40731M.
Mepindolol.
(zzzzt) by omitting item 40737 and substituting the following:
40737.
Mercury for cosmetic or therapeutic use except –
(a) when separately specified in these Schedules; or
(b) in a sealed device which prevents access to the mercury.
(zzzzu) by inserting after item 40738 the following:
40738M.
Mersalyl.
(zzzzv) by inserting after item 40748 the following:
40748S.
Methallenoestril.
(zzzzw) by inserting after item 40756 the following:
40756M.
Methisazone.
(zzzzx) by inserting after item 40758 the following:
40758M.
Methohexitone.
40758S.
Methoin.
(zzzzy) by inserting after item 40759 the following:
40759E.
Methotrimeprazine.
(zzzzz) by inserting after item 40766 the following:
40766M.
Methylergometrine.
(zzzzza) by omitting item 40767 and substituting the following:
40767.
Methylpentynol.
(zzzzzb) by inserting after item 40777 the following:
40777M.
Metriphonate.
(zzzzzc) by inserting after item 40786 the following:
40786E.
Midodrine.
(zzzzzd) by inserting after item 40795 the following:
40795M.
Mitotane.
(zzzzze) by omitting item 40796 and substituting the following:
40796.
Mitozantrone (mitoxantrone).
(zzzzzf) by inserting after item 40799 the following:
40799E.
Molindone.
(zzzzzg) by omitting item 40803 and substituting the following:
40803.
Monoclonal antibodies for therapeutic use except –
(a) in diagnostic test kits; or
(b) when separately specified in these Schedules.
(zzzzzh) by inserting after item 40804 the following:
40804E.
Morazone.
40804M.
Moricizine.
40804S.
Motrazepam.
40804V.
Motretinide.
40804Z.
Mumps vaccine.
(zzzzzi) by inserting after item 40805 the following:
40805M.
Muromonab.
(zzzzzj) by omitting items 40806 and 40807 and substituting the following:
40806.
Mustine (nitrogen mustard).
40807.
Mycophenolic acid (includes mycophenolate mofetil).
(zzzzzk) by inserting after item 40811 the following:
40811M.
Naftidrofuryl.
(zzzzzl) by omitting item 40818 and substituting the following:
40818.
Naproxen except when included in Schedule 2 or 3 .
(zzzzzm) by inserting after item 40820 the following:
40820M.
Nebacumab.
(zzzzzn) by inserting after item 40822 the following:
40822E.
Nefopam.
(zzzzzo) by inserting after item 40827 the following:
40827S.
Nialamide.
(zzzzzp) by inserting after item 40839 the following:
40839E.
Nimorazole.
(zzzzzq) by inserting after item 40842 the following:
40842S.
Nitrendipine.
(zzzzzr) by inserting after item 40846 the following:
40846E.
Nitroxoline.
(zzzzzs) by inserting after item 40855 the following:
40855E.
Norgestrel.
(zzzzzt) by inserting after item 40858 the following:
40858E.
Noxiptyline.
(zzzzzu) by inserting after item 40865 the following:
40865S.
Oestrogens.
(zzzzzv) by inserting after item 40887 the following:
40887M.
Oxaprozin.
(zzzzzw) by inserting after item 40888 the following:
40888M.
Oxethazaine (oxetecaine) except when included in Schedule 2 .
(zzzzzx) by inserting after item 40889 the following:
40889M.
Oxitropium.
(zzzzzy) by omitting item 40892 and substituting the following:
40892.
Oxpentifylline (pentoxifylline).
(zzzzzz) by inserting after item 40904 the following:
40904E.
Pamidronic acid (includes disodium pamidronate).
(zzzzzza) by omitting item 40905 and substituting the following:
40905.
Pancreatic enzymes except –
(a) in preparations containing 20 000 BP units of lipase activity per dosage unit; or
(b) when separately specified in these Schedules.
(zzzzzzb) by inserting after item 40910 the following:
40910S.
Paramethadione.
(zzzzzzc) by inserting after item 40913 the following:
40913M.
Pecazine.
40913S.
Pefloxacin.
(zzzzzzd) by inserting after item 40914E the following:
40914M.
Penbutolol.
(zzzzzze) by inserting after item 40917 the following:
40917S.
Pentagastrin.
(zzzzzzf) by inserting after item 40930 the following:
40930M.
Phenagycodol.
(zzzzzzg) by inserting after paragraph (b) in item 40953 the following:
40953S.
Phthalylsulphathiazole.
(zzzzzzh) by inserting after item 40957 the following:
40957S.
Pinacidil.
(zzzzzzi) by inserting after item 40959 the following:
40959S.
Pipemidic acid.
(zzzzzzj) by inserting after item 40961 the following:
40961E.
Piperidine.
(zzzzzzk) by inserting after item 40963 the following:
40963M.
Pipothiazine.
(zzzzzzl) by inserting after item 40964 the following:
40964E.
Pirbuterol.
(zzzzzzm) by inserting after item 40965 the following:
40965M.
Piretanide.
(zzzzzzn) by inserting after item 40967 the following:
40967M.
Pirprofen.
(zzzzzzo) by inserting after item 40968 the following:
40968M.
Pivampicillin.
(zzzzzzp) by omitting item 40973 and substituting the following:
40973.
Poliomyelitis vaccine.
(zzzzzzq) by inserting after item 40977 the following:
40977E.
Polythiazide.
40977M.
Potassium bromide.
(zzzzzzr) by inserting after item 40988 the following:
40988S.
Prenalterol.
(zzzzzzs) by inserting after item 41001 the following:
41001E.
Progestogens.
41001M.
Proglumide.
(zzzzzzt) by inserting after item 41005 the following:
41005E.
Promoxolane.
41005M.
Propafenone.
(zzzzzzu) by inserting after item 41016 the following:
41016S.
Proscillaridin.
(zzzzzzv) by inserting after item 41018 the following:
41018M.
Protamine sulfate except when included in insulins.
(zzzzzzw) by inserting after item 41019 the following:
41019E.
Prothipendyl.
(zzzzzzx) by inserting after item 41020 the following:
41020S.
Protoveratrines.
(zzzzzzy) by inserting after item 41024 the following:
41024S.
Pyridinolcarbamate.
(zzzzzzz) by inserting after item 41028 the following:
41028S.
Quazepam.
(zzzzzzza) by inserting after item 41034 the following:
41034SS.
Rabies vaccines.
(zzzzzzzb) by inserting after item 41039 the following:
41039E.
Razoxane.
(zzzzzzzc) by inserting after item 41040 the following:
41040M.
Reserpine.
(zzzzzzzd) by omitting item 41044 and substituting the following:
41044.
Rifampicin (rifamycin).
(zzzzzzze) by inserting after item 41057 the following:
41057M.
Rubella vaccine.
(zzzzzzzf) by omitting item 41065 and substituting the following:
41065.
Selenium for therapeutic use except –
(a) when included in Schedule 3 , 6 or 7 ; or
(b) in solid, slow-release bolus preparations, for the treatment of animals, each –
(i) weighing 100 g or more; and
(ii) containing 300 mg or less of selenium; or
(c) as elemental selenium, in pellets containing 100 g/kg or less of selenium, for the treatment of animals; or
(d) in tablets, for the treatment of animals, each –
(i) weighing 2 g or more; and
(ii) containing 30 micrograms or less of selenium; or
(e) in animal feeds containing 1 g/tonne or less of selenium; or
(f) in preparations for oral human use with a recommended daily dose of 26 micrograms or less of selenium; or
(g) in preparations for topical use containing 2.5% or less of selenium sulphide.
(zzzzzzzg) by omitting item 41073 and substituting the following:
41073.
Silicones in injectable preparations for human use except when separately specified in these Schedules.
(zzzzzzzh) by inserting after item 41076 the following:
41076S.
Sodium bromide.
(zzzzzzzi) by omitting item 41078 ;(zzzzzzzj) by inserting after item 41082 the following:
41082S.
Sodium salicylate in preparations for injection for the treatment of animals.
(zzzzzzzk) by inserting after item 41087 the following:
41087S.
Somatostatin.
(zzzzzzzl) by inserting after item 41091 the following:
41091S.
Sparfloxacin.
(zzzzzzzm) by inserting after paragraph (b) in item 41094 the following:
41094E.
Spirapril.
(zzzzzzzn) by inserting after item 41099 the following:
41099E.
Steroid hormones.
(zzzzzzzo) by omitting item 41100 and substituting the following:
41100.
Stilboestrol (diethylstilboestrol).
(zzzzzzzp) by inserting after paragraph (b) in item 41101 the following:
41101M.
Streptodornase.
(zzzzzzzq) by inserting after item 41107 the following:
41107E.
Styramate.
41107M.
Sulbactam.
41107S.
Sulfadimethoxine.
41107V.
Sulfadimidine.
(zzzzzzzr) by inserting after item 41108 the following:
41108E.
Sulfafurazole.
41108M.
Sulfaguanidine.
41108S.
Sulfamethizole.
41108V.
Sulfamethoxydiazine.
41108X.
Sulfamethoxypyridazine.
(zzzzzzzs) by inserting after item 41110 the following:
41110E.
Sulfamoxole.
41110M.
Sulfaphenazole.
41110S.
Sulfapyridine.
41110V.
Sulfasalazine.
41110Z.
Sulfathiazole.
(zzzzzzzt) by inserting after item 41116 the following:
41116S.
Sultamicillin.
(zzzzzzzu) by inserting after item 41118 the following:
41118M.
Suprofen.
41118S.
Sutilains.
(zzzzzzzv) by inserting after item 41122 the following:
41122E.
Tamsulosin.
(zzzzzzzw) by inserting after item 41123 the following:
41123S.
Tazarotene.
(zzzzzzzx) by inserting after item 41124 the following:
41124M.
T-cell receptor antibody.
(zzzzzzzy) by inserting after item 41132 the following:
41132S.
Terodiline.
(zzzzzzzz) by inserting after item 41135 the following:
41135M.
Tetanus antitoxin.
(zzzzzzzza) by inserting after item 41137 the following:
41137M.
Tetraethylammonium.
41137S.
Tetroxoprim.
(zzzzzzzzb) by inserting after item 41148 the following:
41148S.
Thiocarlide.
(zzzzzzzzc) by inserting after item 41150 the following:
41150S.
Thiopentone.
(zzzzzzzzd) by inserting after item 41151 the following:
41151E.
Thioproperazine.
(zzzzzzzze) by omitting item 41153 and substituting the following:
41153.
Thiotepa (triethylene thiophosphoramide).
(zzzzzzzzf) by inserting after item 41163 the following:
41163E.
Tiaramide.
41163M.
Tibolone.
(zzzzzzzzg) by inserting after item 41166 the following:
41166E.
Tienilic acid.
(zzzzzzzzh) by omitting items 41173 and 41174 and substituting the following:
41173.
Tinzaparin (includes tinzaparin sodium).
41174.
Tioconazole except when included in Schedule 2 or 3 .
(zzzzzzzzi) by inserting after item 41184 the following:
41184M.
Tolmetin.
(zzzzzzzzj) by inserting after item 41187 the following:
41187S.
Torasemide.
(zzzzzzzzk) by omitting item 41189 and substituting the following:
41189.
Toxoids for human parenteral use except when separately specified in these Schedules.
(zzzzzzzzl) by inserting after item 41193 the following:
41193M.
Treosulphan.
(zzzzzzzzm) by inserting after item 41196 the following:
41196S.
Triacetyloleandomycin.
(zzzzzzzzn) by inserting after item 41200 the following:
41200S.
Trichlormethiazide.
(zzzzzzzzo) by omitting item 41206 and substituting the following:
41206E.
Trifluperidol (includes the hydrochloride).
41206M.
Triflupromazine.
(zzzzzzzzp) by inserting after item 41213 the following:
41213M.
Triple antigen vaccine.
(zzzzzzzzq) by inserting after item 41214 the following:
41214E.
Triptorelin.
(zzzzzzzzr) by omitting item 41222 and substituting the following:
41222.
Typhoid vaccine.
(zzzzzzzzs) by omitting item 41244E and substituting the following:
41224E.
Urokinase.
41224S.
Ursodeoxycholic acid.
(zzzzzzzzt) by inserting after item 41237 the following:
41237M.
Viloxazine.
(zzzzzzzzu) by inserting after item 41238 the following:
41238S.
Vincamine.
(zzzzzzzzv) by inserting after item 41247 the following:
41247S.
Xamoterol.
(zzzzzzzzw) by inserting after item 41248 the following:
41248E.
Xipamide.
(zzzzzzzzx) by inserting after item 41253 the following:
41253M.
Zimeldine.
(zzzzzzzzy) by inserting after item 41258 the following:
41258M.
Zoxazolamine.
7. Schedule 5 amended (Domestic Poisons)
Schedule 5 to the Principal Order is amended as follows:(a) by omitting item 5006 and substituting the following:
5006.
Alkaline salts, being the carbonate, silicate or phosphate salts of sodium or potassium, alone or in any combination –
(a) in solid orthodontic device cleaning preparations, the pH of which as an in-use aqueous solution is more than 11.5; or
(b) in solid automatic dishwashing preparations the pH of which, in a 500 g/l aqueous solution or mixture is more than 11.5; or
(c) in other solid preparations, the pH of which in a 10g/l aqueous solution is more than 11.5; or
(d) in liquid or semisolid preparations, the pH of which is more than 11.5.
5006E.
Alkoxylated fatty alkylamine polymer in preparations containing 50% or less of alkoxylated fatty alkylamine polymer except in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.
(b) by inserting after item 5017 the following:
5017S.
Azoxystrobin.
(c) by omitting item 5042 and substituting the following:
5042.
Chlorpyrifos –
(a) in aqueous preparations containing 20% or less of microencapsulated chlorpyrifos; or
(b) in controlled-release granular preparations containing 10% or less of chlorpyrifos; or
(c) in other preparations containing 5% or less of chlorpyrifos –
except in prepared potting or soil mixes containing 100 g per cubic metre or less of chlorpyrifos.
(d) by omitting item 5091 ;(e) by inserting after item 5099 the following:
5099M. `
Doramectin for internal use for the treatment of animals, in preparations containing 2% or less of doramectin.
(f) by inserting after item 5174 the following:
5174E.
Mecoprop in preparations containing 2% or less of mecoprop.
(g) by inserting after item 5244 the following:
5244M.
Pymetrozine.
(h) by omitting item 5248 and substituting the following:
5248.
Quaternary ammonium compounds in preparations containing 20% or less of quaternary ammonium compounds except –
(a) when separately specified in these Schedules; or
(b) dialkyl quaternary ammonium compounds where the alkyl groups are derived from tallow or hydrogenated tallow or similar alkyl chain length (C16/C18) sources; or
(c) in preparations containing 5% or less of such quaternary ammonium compounds.
(i) by omitting item 5254 ;(j) by inserting after item 5290 the following:
5290E.
Thiodicarb in pelleted preparations containing 1.5% or less of thiodicarb.
(k) by omitting item 5303 and substituting the following:
5303.
Trichloroisocyanuric acid –
(a) in compressed block form for use in swimming pools or toilet cisterns; or
(b) in granular form for use in swimming pools.
(l) by inserting after item 5306 the following:
5306S.
Trifloxystrobin.
(m) by inserting after item 5308 the following:
5308E.
Triisopropanolamine lauryl ether sulfate except in preparations containing 30% or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:
Avoid contact with eyes and skin; and
Wash hands after handling.
8. Schedule 6 amended (Agricultural and Industrial Poisons)
Schedule 6 to the Principal Order is amended as follows:(a) by inserting after item 6008 the following:
6008S.
Alkoxylated fatty alkylamine polymer except –
(a) when included in Schedule 5 ; or
(b) in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.
(b) by omitting item 6018 ;(c) by inserting after item 6054 the following:
6054E.
2-butoxyethanol and its acetates except in preparations containing 10% or less of such substances.
(d) by omitting item 6076 and substituting the following:
6076.
Chlorpyrifos except –
(a) when included in Schedule 5 ; or
(b) in prepared potting or soil mixes containing 100 g per cubic metre or less of chlorpyrifos.
(e) by omitting item 6146 and substituting the following:
6146.
Doramectin for external use for the treatment of animals, in preparations containing 2% or less of doramectin.
(f) by omitting item 6163 and substituting the following:
6163.
Ethylene glycol monoalkyl ethers and their acetates, except –
(a) when separately specified in these Schedules; or
(b) in preparations containing 10% or less of such substances.
(g) by omitting item 6231M and substituting the following:
6231M.
Mecoprop except when included in Schedule 5 .
(h) by omitting item 6306 and substituting the following:
6306.
Potassium peroxomonosulfate triple salt except –
(a) when included in Schedule 5 ; or
(b) in solid orthodontic device cleaning preparations, the pH of which as an "in-use" aqueous solution is 2.5 or more, but not more than 11.5; or
(c) in preparations containing 5% or less of potassium peroxomonosulfate triple salt being –
(i) solid preparations the pH of which in a 10 g/L aqueous solution is 2.5 or more; or
(ii) liquid or semi-solid preparations the pH of which is 2.5 or more.
(i) by omitting item 6322 and substituting the following:
6322.
Quaternary ammonium compounds except –
(a) when separately specified in these Schedules; or
(b) when included in Schedule 5 ; or
(c) dialkyl quaternary ammonium compounds where the alkyl groups are derived from tallow or hydrogenated tallow or similar alkyl chain length (C16/C18) sources; or
(d) in preparations containing 5% or less of such quaternary ammonium compounds.
(j) by omitting item 6353 and substituting the following:
6353.
Terbuthylazine except in preparations containing 5% or less of terbuthylazine.
(k) by omitting item 6363 and substituting the following:
6363.
Thiodicarb except when included in Schedule 5 .
9. Schedule 7 amended (Dangerous Poisons)
Schedule 7 to the Principal Order is amended as follows:(a) by omitting item 7092 and substituting the following:
7092.
Doramectin except when included in Schedule 5 or 6 .
(b) by omitting item 7195 and substituting the following:
7195.
Selenium except –
(a) when included in Schedule 6 ; or
(b) as selenium arsenide in photocopier drums; or
(c) in preparations for therapeutic use other than –
(i) drench concentrates containing 2.5% or less of selenium; or
(ii) pour-on preparations containing 0.5% or less of selenium; or
(d) in fertilisers containing 200 g/tonne or less of selenium.
Displayed and numbered in accordance with the Rules Publication Act 1953.
Notified in the Gazette on 16 June 1999
This order is administered in the Department of Health and Human Services.
EXPLANATORY NOTE
(This note is not part of the order)
This order amends the Poisons List in force under section 14 of the Poisons Act 1971 so as to adopt changes recommended by the National Drugs and Poisons Schedule Committee.